445 related articles for article (PubMed ID: 17120686)
1. [The role of biological agents in the treatment of psoriatic arthritis, literature review].
Koó E; Brodszky V; Péntek M; Ujfalussy I; Nagy MB; Gulácsi L
Orv Hetil; 2006 Oct; 147(41):1963-70. PubMed ID: 17120686
[TBL] [Abstract][Full Text] [Related]
2. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
3. Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.
Kirson NY; Rao S; Birnbaum HG; Kantor E; Wei RS; Cifaldi M
J Med Econ; 2013; 16(4):479-89. PubMed ID: 23339434
[TBL] [Abstract][Full Text] [Related]
4. Safety of anti-TNFα agents in the treatment of psoriasis and psoriatic arthritis.
Girolomoni G; Altomare G; Ayala F; Berardesca E; Calzavara-Pinton P; Chimenti S; Peserico A; Puglisi Guerra A; Vena GA
Immunopharmacol Immunotoxicol; 2012 Aug; 34(4):548-60. PubMed ID: 22296031
[TBL] [Abstract][Full Text] [Related]
5. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials.
Saad AA; Symmons DP; Noyce PR; Ashcroft DM
J Rheumatol; 2008 May; 35(5):883-90. PubMed ID: 18381787
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of psoriatic arthritis with TNF alpha-antagonists].
Antoni C; Manger B
Z Rheumatol; 2003 Jun; 62(3):235-9. PubMed ID: 12827399
[TBL] [Abstract][Full Text] [Related]
7. Sustained clinical response in psoriatic arthritis patients treated with anti-TNF agents: a 5-year open-label observational cohort study.
Saougou I; Markatseli TE; Papagoras C; Voulgari PV; Alamanos Y; Drosos AA
Semin Arthritis Rheum; 2011 Apr; 40(5):398-406. PubMed ID: 20843542
[TBL] [Abstract][Full Text] [Related]
8. Update on anti-tumor necrosis factor therapy in the spondyloarthropathies including psoriatic arthritis.
Kavanaugh A; Tutuncu Z; Catalan-Sanchez T
Curr Opin Rheumatol; 2006 Jul; 18(4):347-53. PubMed ID: 16763453
[TBL] [Abstract][Full Text] [Related]
9. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.
Kristensen LE; Englund M; Neovius M; Askling J; Jacobsson LT; Petersson IF
Ann Rheum Dis; 2013 Oct; 72(10):1675-9. PubMed ID: 23148309
[TBL] [Abstract][Full Text] [Related]
10. [Recommendations for the appropriate use of anti-TNFalpha therapy in patients with psoriatic arthritis. Italian Rheumatology Society].
Salvarani C; Olivieri I; Cantini F; Marchesoni A; Punzi L; Scarpa R; Matucci-Cerinic M
Reumatismo; 2004; 56(3):133-4, 136-8. PubMed ID: 15470517
[No Abstract] [Full Text] [Related]
11. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
12. Infliximab treatment in psoriatic arthritis: our experience.
Rioda WT; Adorni G
Acta Biomed; 2006 Aug; 77(2):95-102. PubMed ID: 17172189
[TBL] [Abstract][Full Text] [Related]
13. [Anti-TNF alpha in the treatment of psoriatic arthritis].
Claudepierre P; Wendling D; Cohen JD
Presse Med; 2006 Apr; 35(4 Pt 2):647-55. PubMed ID: 16614610
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of psoriatic arthritis therapies.
Gladman DD
Semin Arthritis Rheum; 2003 Aug; 33(1):29-37. PubMed ID: 12920694
[TBL] [Abstract][Full Text] [Related]
15. [The role of biologic agents in the therapy of ankylosing spondylitis].
Géher P; Nagy MB; Péntek M; Tóth E; Brodszky V; Gulácsi L
Orv Hetil; 2006 Jul; 147(26):1203-13. PubMed ID: 16898082
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.
Zink A; Strangfeld A; Schneider M; Herzer P; Hierse F; Stoyanova-Scholz M; Wassenberg S; Kapelle A; Listing J
Arthritis Rheum; 2006 Nov; 54(11):3399-407. PubMed ID: 17075823
[TBL] [Abstract][Full Text] [Related]
17. TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.
Tobin AM; Kirby B
BioDrugs; 2005; 19(1):47-57. PubMed ID: 15691217
[TBL] [Abstract][Full Text] [Related]
18. Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis.
Fénix-Caballero S; Alegre-del Rey EJ; Castaño-Lara R; Puigventós-Latorre F; Borrero-Rubio JM; López-Vallejo JF
J Clin Pharm Ther; 2013 Aug; 38(4):286-93. PubMed ID: 23590560
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital.
Wick MC; Ernestam S; Lindblad S; Bratt J; Klareskog L; van Vollenhoven RF
Scand J Rheumatol; 2005; 34(5):353-8. PubMed ID: 16234182
[TBL] [Abstract][Full Text] [Related]
20. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
Conti F; Ceccarelli F; Marocchi E; Magrini L; Spinelli FR; Spadaro A; Scrivo R; Valesini G
Ann Rheum Dis; 2007 Oct; 66(10):1393-7. PubMed ID: 17613555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
